Is Lp(a) a risk factor for cardiovascular disease and is it worth treating?
Session:
Cardiovascular risk reduction and dyslipidaemia management: current state and future therapies
Topic:
Lipids (Epidemiology and Prevention)
Speaker:
Professor E. Stroes (Amsterdam, NL)
Sponsored by Cleveland Clinic
Event:
ESC Congress 2017
Congress Presentation
About the speaker
Professor Erik Stroes
Academic Medical Centre, Amsterdam (Netherlands (The))
39
presentations
0
follower
3 more presentations in this session
PCSK9 inhibitors post Fourier: who should be treated and when?
Speaker: Professor S. Nissen (Cleveland, US)
siRNA therapy: the dawn of a new agent in cholesterol lowering?
Speaker: Doctor L. Cho (Cleveland, US)
Current state of knowledge on the mechanism of action of bempedoic acid and its potential for LDL-C lowering and CV risk reduction.
Speaker: Professor S. Nicholls (Melbourne, AU)
Access the full session
Cardiovascular risk reduction and dyslipidaemia management: current state and future therapies
Speakers:
Professor E. Stroes, Professor S. Nissen, Doctor L. Cho, Professor S. Nicholls
About the event
ESC 365 is supported by
